FC004 / Sun Yat-sen University - LARVOL DELTA

Mesothelin-targeted CAR-T therapy FC004 for platinum-resistant ovarian cancer: A phase I trial (AACR 2025) - "Patients were pre-treated with albumin-bound paclitaxel, cyclophosphamide, and fludarabine, then received a single infusion of FC004. Preliminary results suggest that FC004 CAR-T cell therapy may have limited efficacy in treating platinum-resistant ovarian cancer. One patient achieved SD, while the other experienced significant toxicities, including severe CRS and pulmonary infection. The infection may have been exacerbated by prior high-dose steroids use, but a relationship with FC004 cannot be ruled out."

IO biomarker • P1 data • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • MSLN • MUC16